While both drugs inhibit VEGF, Ranibizumab is FDA-approved for ocular conditions and is more expensive than Bevacizumab, which is used off-label but offers comparable efficacy.
What is the difference between Bevacizumab and Ranibizumab (Lucentis)?
Share This Story, Choose Your Platform!
About the Author: Staff Writer
World Eyecare Foundation staff writers are experienced eye care providers, researchers, academicians, industry leaders and practicing ophthalmologists and optometrist from around the world. Content may be generated by AI and is reviewed by the editorial team and specialists in the areas of publications.
Leave A Comment